These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31290664)

  • 41. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 42. PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703.
    Wang F; Li Y; Han Y; Zhang Y; Wang H; Wang L; Wang C; Guo M; Li P
    Med Oncol; 2024 Jul; 41(8):207. PubMed ID: 39043895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
    De Haven Brandon A; Box G; Hallsworth A; Court W; Matthews N; Herodek B; Arteagabeitia AB; Valenti M; Kirkin V
    Sci Rep; 2020 Jul; 10(1):10799. PubMed ID: 32612269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Higher EpCAM-Positive Extracellular Vesicle Concentration in Ascites Is Associated with Shorter Progression-Free Survival of Patients with Advanced High-Grade Serous Carcinoma.
    Herzog M; Verdenik I; Kobal B; Černe K
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N
    BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
    Fan L; Zhang W; Yin M; Zhang T; Wu X; Zhang H; Sun M; Li Z; Hou Y; Zhou X; Lou G; Li K
    Acta Oncol; 2012 Apr; 51(4):473-9. PubMed ID: 22283470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
    Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
    [No Abstract]   [Full Text] [Related]  

  • 48. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing.
    Cybulska P; Stewart JM; Sayad A; Virtanen C; Shaw PA; Clarke B; Stickle N; Bernardini MQ; Neel BG
    Am J Pathol; 2018 May; 188(5):1120-1131. PubMed ID: 29458007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Multistep Tumor Growth Model of High-Grade Serous Ovarian Carcinoma Identifies Hypoxia-Associated Signatures.
    More MH; Varankar SS; Naik RR; Dhake RD; Ray P; Bankar RM; Mali AM; Subbalakshmi AR; Chakraborty P; Jolly MK; Bapat SA
    Cells Tissues Organs; 2024; 213(2):79-95. PubMed ID: 35970135
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.
    Bapat J; Yamamoto TM; Woodruff ER; Qamar L; Mikeska RG; Aird KM; Watson ZL; Brubaker LW; Bitler BG
    Cancer Gene Ther; 2024 Feb; 31(2):300-310. PubMed ID: 38030811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management.
    Bradbury M; Borràs E; Vilar M; Castellví J; Sánchez-Iglesias JL; Pérez-Benavente A; Gil-Moreno A; Santamaria A; Sabidó E
    J Transl Med; 2022 Dec; 20(1):611. PubMed ID: 36544142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment.
    Xu J; Lu W; Wei X; Zhang B; Yang H; Tu M; Chen X; Wu S; Guo T
    Cancer Lett; 2024 Jul; 593():216928. PubMed ID: 38714290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.
    Garg G; Yilmaz A; Kumar P; Turkoglu O; Mutch DG; Powell MA; Rosen B; Bahado-Singh RO; Graham SF
    Metabolomics; 2018 Nov; 14(12):154. PubMed ID: 30830441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC/Q-TOF MS.
    Yang W; Mu T; Jiang J; Sun Q; Hou X; Sun Y; Zhong L; Wang C; Sun C
    Cell Physiol Biochem; 2018; 51(3):1134-1148. PubMed ID: 30476914
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
    Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
    Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Hou X; Zhai Y; Hu K; Liu CJ; Udager A; Pearce CL; Fearon ER; Cho KR
    Gynecol Oncol; 2022 Jun; 165(3):552-559. PubMed ID: 35414426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-grade ovarian serous carcinomas: Significant correlation of histologic patterns with IMP3 and E-Cadherin predicting disease recurrence and survival.
    Mohanty SK; Tiwari A; Singh C; Walsh C; Chuang F; Kim E; Singh K; Dadmanesh F
    Ann Diagn Pathol; 2019 Jun; 40():30-39. PubMed ID: 30921622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.